Skip to main content
Beginner 6 min read

Pluvicto (Lutetium-177): What to Expect

Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) is a targeted radioactive medicine (radioligand therapy) used to help treat advanced prostate cancer

NCI source:National Cancer Institute — Lutetium Lu 177 Vipivotide Tetraxetan

Review status: AI-assisted, editorial review complete. Not reviewed by a clinician. How we check pages

The short answer

Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) is a targeted radioactive medicine (radioligand therapy). It carries a small amount of radiation directly to prostate cancer cells by attaching to a protein (PSMA) on their surface, delivering the radiation where it is needed. It is used to help treat advanced prostate cancer that makes the PSMA protein, and is usually given as an IV injection of a radioactive medicine, in a hospital setting. Like all cancer medicines it can cause side effects; this page explains the common ones and the warning signs to report. It is educational only and not a substitute for your care team's advice.

  • Pluvicto is the brand name; its generic name is lutetium Lu 177 vipivotide tetraxetan.

  • It is a targeted radioactive medicine (radioligand therapy) — it carries a small amount of radiation directly to prostate cancer cells by attaching to a protein (PSMA) on their surface, delivering the radiation where it is needed.

  • It is used to help treat advanced prostate cancer that makes the PSMA protein.

  • It is usually given as an IV injection of a radioactive medicine, in a hospital setting.

Choose how you want to read this

The whole article, with every detail and caution.

This page is for men with prostate cancer who are being offered Pluvicto, and their families. It covers how it works, who qualifies, the course of treatment, radiation safety at home, side effects, and when to get help.

A scan decides whether you qualify

Pluvicto is the brand name. Lutetium Lu 177 vipivotide tetraxetan is the generic name. It has two halves joined together. One half seeks out PSMA, a protein found on the surface of many prostate cancer cells. The other half is lutetium-177, a radioactive atom that fires short-range radiation into whatever it is attached to.

Because it only works where PSMA is present, a PET scan comes first. Your team uses an approved PSMA imaging agent to see whether your tumors light up. If they do not, this treatment is not for you. That scan is the gate, and it is worth asking to have the result explained.

Who the label covers

Pluvicto is for adults with PSMA-positive prostate cancer that has spread (metastatic). The FDA label, updated in 2026, covers two groups.

  • Cancer that still responds to hormone therapy, or has not had it yet. Here Pluvicto is given together with an androgen receptor pathway inhibitor (ARPI). This class includes tablets such as enzalutamide and abiraterone.
  • Cancer that has stopped responding to hormone therapy. Here you must already have had an ARPI. You must also either have had taxane chemotherapy, or your team judges it right to delay taxane chemotherapy.

Ask your team which group you are in, and why.

Six doses, six weeks apart

The course is six doses into a vein, about six weeks apart, so the whole treatment spans most of a year. Treatment stops earlier if the cancer grows or side effects make it unwise. The radioactive amount in each dose is fixed by the label and measured out by the nuclear medicine team. It is not a number you handle, so it is not printed here.

The injection itself is quick. The visit is longer, because of preparation, checks and radiation handling. Blood tests and kidney function are reviewed before each dose.

Radiation safety in the days after a dose

You go home mildly radioactive, and the label sets out what to do about it.

  • Drink plenty and empty your bladder often, both before and after the dose. This clears the drug faster and reduces the radiation dose to your bladder.
  • Keep more than 3 feet away from other people where you can for 2 days, and from children and pregnant women for 7 days.
  • Sleep in a separate room from other adults for 3 days, from children for 7 days, and from a pregnant woman for 15 days.
  • Avoid sexual activity for 7 days.

Your nuclear medicine team will give you written instructions, including toilet and hand-washing steps. Keep them where you can find them.

Dry mouth, blood counts and kidneys

The label lists tiredness, dry mouth and nausea among the most common side effects. Ask your team how to ease dry mouth.

The label warns that Pluvicto can cause severe and life-threatening low blood counts. Report unusual tiredness, pallor, breathlessness, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat or mouth ulcers.

The label says to stay well hydrated and urinate often, because the drug can harm the kidneys. Kidney blood tests are checked before and during the course. The label also notes that treatment may cause temporary or permanent infertility, which is worth raising before the first dose.

When to get help sooner

  • Call 911 or go to an emergency department if bleeding will not stop, you are breathless at rest and very pale, or you stop passing urine altogether. Do not drive yourself.
  • Treat a fever as an emergency, not a same-day call. If your temperature reaches 100.4°F (38°C) or higher, or you get shaking chills, phone the oncology or nuclear medicine line right away. If you cannot reach anyone, go to the emergency room. CDC says to call your doctor immediately for a fever of 100.4°F (38°C) or higher during chemotherapy, and calls it a medical emergency. Pluvicto can also lower blood counts, so this holds between visits too.
  • Call your care team right away, day or night, if you get a sore throat, mouth ulcers, or burning when passing urine, even without a fever.
  • Call your care team within a day or two if you bruise for no reason, feel worn out beyond your usual, cannot keep fluids down, or your urine volume drops while you are trying to drink more.

Say that you have had a radioactive treatment when you call, and take your written radiation-safety instructions with you.

Sources

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a

https://www.cancer.gov/about-cancer/treatment/drugs/lutetium-lu-177-vipivotide-tetraxetan

A woman in a headscarf sits in a medical chair talking with a man, IV pole nearby

Common questions

What is Pluvicto?

Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) is a targeted radioactive medicine (radioligand therapy). It carries a small amount of radiation directly to prostate cancer cells by attaching to a protein (PSMA) on their surface, delivering the radiation where it is needed. It is used to help treat advanced prostate cancer that makes the PSMA protein.

How is Pluvicto given?

It is usually given as an IV injection of a radioactive medicine, in a hospital setting. It is given as an injection into a vein, on a repeating schedule. Because it is radioactive, your team gives you simple safety steps to follow for a short time after each dose. The exact schedule is set by your care team.

What are the common side effects of Pluvicto?

Commonly reported side effects include tiredness, dry mouth, nausea, and low blood counts. Not everyone gets them, and many can be managed. Tell your care team about anything new or worsening.

Does Pluvicto cure cancer?

Pluvicto is approved for prostate cancer that has spread. Ask your care team what the goal is in your situation, such as slowing the cancer or easing symptoms, and how you will know if it is working.

Questions to ask your doctor

Being prepared helps you get the most out of your appointments. Save or print these questions.

Open my question list

Tap a question to save it to your list (kept on this device).

Talk to a person

Talk with a trained specialist or navigator

Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.

Free & Confidential

Talk to a trained cancer information specialist

Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.

Contact your oncology team

Locate after-hours contact numbers, portal messages, or urgent triage phone lines.

Find a patient navigator

Get one-on-one help with appointments, logistics, translation, and care coordination.

Find a genetic counselor

Discuss inherited mutation risk, family history, and genetic testing options.

Find an oncology social worker

Access emotional counseling, family support groups, and mental health resources.

Find a financial navigator

Locate copay assistance foundations, grant programs, and lodging/travel support.

Find a clinical-trial specialist

Search matching studies and speak with NCI trial information specialists.

Get urgent help

Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.

Know someone who needs this?

Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.

Email itText itWhatsApp

Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.

Prepared by Cancer Explained's AI-assisted editorial system

Written from National Cancer Institute material and compared with the source cited below.

Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.

Sources last checked: 2026-08-13 what this meansLast updated: 2026-09-30Next planned review: 2027-01-14

Review details and limits

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status — Editorial review complete. This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.

General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Our editorial processHow we use AIReport an error

More on this topic

Words to know

Tap any term to see what it means.

Browse the full glossary →

Knowledge check

0 of 2 answered

  1. Q1.What kind of medicine is Pluvicto?
  2. Q2.Which of these is Pluvicto used to help treat?

This self-assessment checks understanding of educational content only. It is not medical advice.

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status: Editorial review complete — This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Read more about our editorial process, our use of AI, and our corrections policy.

Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.

After using this page, do you understand what to do next?

Anonymous — we only record the answer, never who gave it.